MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

Home・Aktien・Talphera Inc.

Talphera Inc.

Open

0.99 -1

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.96

Max

1.03

Schlüsselkennzahlen
By Trading Economics
Angestellte	13

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+198.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-12M 49M
Vorheriger Eröffnungskurs	1.99
Vorheriger Schlusskurs	0.99

Talphera Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Jan. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. Jan. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. Jan. 2026, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. Jan. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. Jan. 2026, 20:54 UTC

Ergebnisse

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. Jan. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. Jan. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. Jan. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. Jan. 2026, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. Jan. 2026, 19:22 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. Jan. 2026, 18:21 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. Jan. 2026, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. Jan. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. Jan. 2026, 18:16 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. Jan. 2026, 18:01 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. Jan. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer-Vergleich

Kursveränderung

Talphera Inc. Prognose

Kursziel

By TipRanks

198.17% Vorteil

12-Monats-Prognose

Durchschnitt 3.25 USD 198.17%

Hoch 3.5 USD

Tief 3 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Talphera Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Talphera Inc. – Dist abgegeben haben.

Finanzen

Über Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.